The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 1, 2008, Pages 103-109

  Deresinski, Stanley C ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Antimicrobial; Ceftobiprole; Cephalosporin; Complicated skin and skin structure infection; Gram negative; Gram positive; MRSA; Staphylococcus aureus

Indexed keywords

AZTREONAM; C REACTIVE PROTEIN; CEFTAZIDIME; CEFTOBIPROLE; METRONIDAZOLE; VANCOMYCIN;

ACINETOBACTER; ANAPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIABETIC FOOT; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE INFECTION; HEADACHE; HUMAN; HYPERSENSITIVITY; INJECTION SITE REACTION; INSOMNIA; KIDNEY DYSFUNCTION; KLEBSIELLA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORGANELLA MORGANII; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROTEUS MIRABILIS; PRURITUS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; RASH; SERRATIA MARCESCENS; SKIN ALLERGY; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; URTICARIA; VOMITING;

CEPHALOSPORINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME;

EID: 41949123083     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.03.004     Document Type: Article

References (22)

1. Artigas V., Serra J., Calabuig R., Garcia P., Allende L., and Rius X. Perineal necrotizing infection. Curr. Surg. 47 (1990) 4-7
2. Boyle-Vavra S., and Daum R.S. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab. Invest. 87 (2007) 3-9
3. Cabrera H., Skoczdopole L., Marini M., Della Giovanna P., Saponaro A., and Echeverria C. Necrotizing gangrene of the genitalia and perineum. Int. J. Dermatol. 41 (2002) 847-851
4. Daum R.S. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N. Engl. J. Med. 357 (2007) 380-390
5. Davis S.L., Perri M.B., Donabedian S.M., Manierski C., Singh A., Vager D., Haque N.Z., Speirs K., Muder R.R., Robinson-Dunn B., Hayden M.K., and Zervos M.J. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol. 45 (2007) 1705-1711
6. DiNubile M.J., and Lipsky B.A. Complicated infections of skin and skin structures: when the infection is more than skin deep. J. Antimicrob. Chemother. 53 (2004) ii37-ii50
7. Drugs.com. New drug application submitted for novel investigational antibiotic ceftobiprole. Available at: (2007). http://www.drugs.com/nda/ceftobiprole_070518.html Accessed November 16
8. Han L.L., McDougal L.K., Gorwitz R.J., Mayer K.H., Patel J.B., Sennott J.M., and Fontana J.L. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J. Clin. Microbiol. 45 (2007) 1350-1352
9. King M.D., Humphrey B.J., Wang Y.F., Kourbatova E.V., Ray S.M., and Blumberg H.M. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144 (2006) 309-317
10. Kollef M.H. Appropriate empirical antibacterial therapy for nosocomial infections. Getting it right for the first time. Drugs 63 (2003) 2157-2168
11. Lee S.Y., Kuti J.L., and Nicolau D.P. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg. Infect. 6 (2005) 283-295
12. Lipsky B.A., Weigelt J.A., Gupta V., Killian A., and Peng M.M. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect. Control Hosp. Epidemiol. 28 (2007) 1290-1298
13. Miller L.G., Perdreau-Remington F., Bayer A.S., Diep B., Tan N., Bharadwa K., Tsui J., Perlroth J., Shay A., Tagudar G., Ibebuogu U., and Spellberg B. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin. Infect. Dis. 44 (2007) 471-482
14. Moet G.J., Jones R.N., Biedenbach D.J., Stilweel M.G., and Fritsche T.R. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY antimicrobial surveillance program (1998-2004). Diagn. Microbiol. Infect. Dis. 57 (2007) 7-13
15. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., Talan D.A., and EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355 (2006) 666-674
16. Nichols R.L. Optimal treatment of complicated skin and skin structure infections. J Antimicrob. Chemother. 44 Suppl A (1999) 19-23
17. Noel G.J., Strauss R.S., Amsler K., Heep M., Pypstra R., and Solomkin J.S. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob. Agents Chemother. 52 (2008) 37-44
18. Noel G.J., Bush K., Bagchi P., Ianus J., and Strauss R.S. A randomized, double-blind trial comparing ceftobiprole medocaril to vancomycin plus ceftazidime in the treatment of patients with complicated skin and skin structure infection. Clin. Infect. Dis. 46 (2008) 647-655
19. Rennie R.P., Jones R.N., Mutnick A.H., and and the SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada 2000). Diagn. Microbiol. Infect. Dis. 45 (2003) 287-293
20. Strauss R.S., Bagchi P., Noel G.J., and and the BAP00414 Study Group. Ceftobiprole compared to vancomycin plus ceftazidime in the treatment of patients with diabetic foot infections. Presented at: the 45th Annual Meeting of the Infectious Diseases Society of America (IDSA); October 4-7, 2007; San Diego, CA. Poster 1086 (2007)
21. Styers D., Sheehan D.J., Hogan P., and Sahm D.F. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5 (2006) 2
22. Taviloglu K., Cabioglu N., Cagatay A., Yanar H., Ertekin C., Baspinar I., Ozsut H., and Guloglu R. Idiopathic necrotizing fasciitis: risk factors and strategies for management. Am. Surg. 71 (2005) 315-320